Stocks and Investing
Stocks and Investing
Wed, April 3, 2024
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
[ Wed, Apr 03rd 2024
] - WOPRAI
Asthika Goonewardene Maintained (STRO) at Strong Buy with Decreased Target to $18 on, Apr 3rd, 2024
Asthika Goonewardene of Truist Securities, Maintained "Sutro Biopharma, Inc." (STRO) at Strong Buy with Decreased Target from $25 to $18 on, Apr 3rd, 2024.
Asthika has made no other calls on STRO in the last 4 months.
There are 2 other peers that have a rating on STRO. Out of the 2 peers that are also analyzing STRO, 0 agree with Asthika's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Asthika
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $16 on, Tuesday, March 26th, 2024
- David Nierengarten of "Wedbush" Maintained at Buy with Decreased Target to $8 on, Tuesday, March 26th, 2024
Contributing Sources